Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Jean‐François Baurain
ResearcherPublications, citations & collaboration network
Jean‐François Baurain is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 275 works, 11,913 citations, an h-index of 36 and an i10-index of 81.
275
Works
11,913
Citations
36
h-index
81
i10-index
How has Jean‐François Baurain's publication output changed over time?
ScholarIQpublication output · 1997–2024
Output grew0% over the shown period — from 1 works in 1997 to 1 in 2024.
1
2
1
1
3
2
1
1997200920112012202120232024
What are the most-cited papers on Jean‐François Baurain?
ScholarIQmost cited works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok
New England Journal of Medicine. 20114,477 CitationsOPEN ACCESS
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K.S. Salama, Brendan D. Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno‐Neumann
New England Journal of Medicine. 2021897 CitationsOPEN ACCESS
Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann, Nicolas van Baren, Jean‐François Baurain, Charles De Smet, Hérvè Chambost, Massimo Vitale, Alessandro Moretta, Thierry Boon, Pierre G. Coulie
S199671312. 1997774 CitationsOPEN ACCESS
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent, Alba A. Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Alain Carpentier, Paul M. Clément, M. Frénay, Mario Campone, Jean‐François Baurain, Jean-Paul Armand, Martin Taphoorn, Alicia Tosoni, Heidemarie Kletzl, Barbara Klughammer, Denis Lacombe, Thierry Gorlia
Journal of Clinical Oncology. 2009573 CitationsOPEN ACCESS
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia
The Lancet Oncology. 2021401 Citations
Related on ScholarIQ
Cliniques Universitaires Saint-Luc
Institution
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Paper
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paper
Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
Paper
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Paper
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Paper